Showing 91-100 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Spatial and temporal regulation of proangiogenic factors to support islet cell transplantation | William Marsh Rice University | Omid Veiseh | Cures | 01-January-2025 to 31-December-2027 | $900.000,00 |
| A Novel Bifunctional Biologic for Type 1 Diabetes | Johns Hopkins University | Giorgio Raimondi | Cures | 01-February-2025 to 31-January-2028 | $995.376,00 |
| Understanding Disease Mechanisms Underlying Type 1 Diabetes | Baylor College of Medicine | Ashok Balasubramanyam | Cures | 01-November-2024 to 31-October-2027 | $967.091,04 |
| bifunctional RNA therapeutics for T1D | University of Miami | Paolo Serafini | Cures | 01-February-2025 to 31-January-2028 | $900.000,00 |
| Moving the field forward: A landscape review of psychosocial, behavioral and mental health in Type 1 diabetes | Penn State College of Medicine | Heather Stuckey | Improving Lives | 01-October-2024 to 31-March-2026 | $71.613,88 |
| Autoimmunity Screening for Kids (ASK) | Regents of the University of Colorado | Marian Rewers | Cures | 01-November-2024 to 31-October-2027 | $3.074.807,75 |
| The KQ1 serum study: amendment & extension | Icahn School of Medicine at Mount Sinai | Dirk Homann | Cures | 01-November-2024 to 31-October-2027 | $1.873.290,24 |
| Improving the Uptake and Applicability of the Clinical and Economic Optimization Platform for Type 1 Diabetes Screening | Regents of the University of Colorado | R. Brett McQueen | Cures | 01-September-2024 to 31-August-2026 | $451.890,07 |
| Development of an injectable immunomodulatory niche technology for induction of immune tolerance to islet cell transplants | Stanford University | Eric Appel | Cures | 01-January-2025 to 31-December-2026 | $600.000,00 |
| Exploiting SDF2L1 to protect against beta cell death and dysfunction in T1D | Indiana Biosciences Research Institute | Michael Kalwat | Cures | 01-December-2024 to 30-November-2027 | $748.169,00 |